Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose tissue derived stromal vascular fraction
- Development stage
- Unknown
- Lead developer
- American CryoStem
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-articular Injection, Subcutaneous Injection, Surgical Implantation/injection (site-specific)
01
Overview
Autologous adipose tissue derived stromal vascular fraction (AD-tSVF) is a heterogeneous mixture of cells isolated from a patient's own (autologous) fat tissue. This cell population includes mesenchymal stem cells (MSCs), endothelial cells, pericytes, immune cells (such as T-cells), and other progenitor and support cells. The primary mechanism of action is believed to be regenerative and immunomodulatory; the MSCs within the SVF can differentiate into various cell types including bone, cartilage, and muscle. Additionally, these cells secrete paracrine factors that modulate inflammation and promote tissue repair. AD-tSVF is being investigated for use in regenerative medicine applications such as osteoarthritis treatment and reconstructive surgery due to its potential to reduce inflammation and stimulate regeneration in damaged tissues[1][2][4].
- Other names
- adipose-derived stromal vascular fraction cellsautologous SVFadipose-derived regenerative cell therapy
Beyond the preview
Go deeper on autologous adipose tissue derived stromal vascular fraction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose tissue derived stromal vascular fraction.